Describing distance: from the plane to spectral triples

Analysis and Stochastic

Veronese and Segre morphisms between non-commutative projective spaces

Number theory, Algebra and Geometr

Associated noncommutative vector bundles over the Vaksman–Soibelman quantum complex projective spaces

Analysis and Stochastic

Acute deep vein thrombosis in COVID 19 hospitalized patients. Risk factors and clinical outcomes

Nello studio vengono analizzati i fattori di rischio in pazienti con infezione da COVID 19 e trombosi venosa profond

An equivariant pullback structure of trimmable graph C^*-algebras

To unravel the structure of fundamental examples studied in noncommutative topology, we prove that the graph C*-algebra C*(E) of a trimmable graph E is U(1)-equivariantly iso-morphic to a pullback C *-algebra of a subgraph C *-algebra C*(E'') and the C *-algebra of func-tions on a circle tensored with another subgraph C*-algebra C*(E'). This allows us to approach the structure and K-theory of the fixed-point subalgebra C*(E)U .1/ through the (typically simpler) C *-algebras C*(E'), C*(E'') and C*(E'')U.1/. As examples of trimmable graphs, we consider one-loop extensions of the standard graphs encoding respectively the Cuntz algebra O2 and the Toeplitz algebra T . Then we analyze equivariant pullback structures of trimmable graphs yielding the C*-algebras of the Vaksman-Soibelman quantum sphere S2n+1 q and the quantum lens space L3 q(l;1, l), respectively.Analysis and Stochastic

Differential core pharmacotherapy in bipolar I versus bipolar II disorder and European versus American patients not in a syndromal episode

Assess bipolar disorder subtype and treatment location effects on bipolar disorder core pharmacotherapy. Outpatients not in a syndromal episode referred to the University of Milan and Stanford University Bipolar Disorder Clinics were assessed with SCID for the fourth Edition of the Diagnostic and Statistical Manual of Mood Disorders, and the Systematic Treatment Enhancement Program for Bipolar Disorder Affective Disorders Evaluation, respectively. Prevalence and clinical correlates of antidepressant, antipsychotic, and mood stabilizer use, in aggregate and individually, were compared in bipolar I (BDI) versus II (BDII) patients in Milan/Stanford and in Milan versus Stanford patients, stratified by subtype. Milan/Stanford pooled BDI versus BDII patients significantly more often took antipsychotic (69.8 versus 44.8%), mood stabilizers (68.6 versus 57.7%), and valproate (40.1 versus 17.5%), and less often took antidepressants (23.1 versus 55.6%) and lamotrigine (9.9 versus 25.2%). Milan versus Stanford patients (stratified by bipolar disorder subtype) significantly more often took antipsychotic (BDI and BDII), antidepressants (BDII), and valproate (BDII), and less often took lamotrigine (BDI). Research regarding bipolar disorder core pharmacotherapy relationships with bipolar subtype and treatment location is warranted to enhance clinical management

Isomeric ratios in Hg-206

T. Alexander et al.; 5 págs.; 2 figs.; 1 tab.; PACS numbers: 25.70.Mn, 23.35.+g, 27.80.+w; Presented at the Zakopane Conference on Nuclear Physics “Extremes of the Nuclear Landscape”, Zakopane, Poland, August 31–September 7, 2014.206Hg was populated in the fragmentation of an E∕A = 1 GeV 208Pb beam at GSI. It was part of a campaign to study nuclei around 208Pb via relativistic Coulomb excitation. The observation of the known isomeric states confirmed the identification of the fragmentation products. The isomeric decays were also used to prove that the correlations between beam identification detectors and the AGATA γ-ray tracking array worked properly and that the tracking efficiency was independent of the time relative to the prompt flash.Peer Reviewe

Effect of comorbidities on survival in patients > 80 years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry

Background. The number of elderly patients on renal replacement therapy (RRT) is increasing. The survival and quality of life of these patients may be lower if they have multiple comorbidities at the onset of RRT. The aim of this study was to explore whether the effect of comorbidities on survival is similar in elderly RRT patients compared with younger ones. Methods. Included were 9333 patients >= 80years of age and 48352 patients 20-79 years of age starting RRT between 2010 and 2015 from 15 national or regional registries submitting data to the European Renal Association-European Dialysis and Transplantation Association Registry. Patients were followed until death or the end of 2016. Survival was assessed by Kaplan-Meier curves and the relative risk of death associated with comorbidities was assessed by Cox regression analysis. Results. Patients >= 80years of age had a greater comorbidity burden than younger patients. However, relative risks of death associated with all studied comorbidities (diabetes, ischaemic heart disease, chronic heart failure, cerebrovascular disease, peripheral vascular disease and malignancy) were significantly lower in elderly patients compared with younger patients. Also, the increase in absolute mortality rates associated with an increasing number of comorbidities was smaller in elderly patients. Conclusions. Comorbidities are common in elderly patients who enter RRT, but the risk of death associated with comorbidities is less than in younger patients. This should be taken into account when assessing the prognosis of elderly RRT patients.Peer reviewe

Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial

BACKGROUND: Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-alpha monoclonal antibody, might relieve pain. METHODS: A randomized placebo-controlled trial was designed with 21 women with severe pain and a rectovaginal nodule of at least 1 cm. After 1 month of observation, three infusions of infliximab (5 mg/kg) or placebo were given. Surgery was performed 3 months later and follow-up continued for 6 months. The primary end-point was pain (dysmenorrhea, deep dyspareunia and non-menstrual pain) rated at each visit by the clinician and on a daily basis by the patient who in addition scored pain by visual analog pain scale and analgesia intake. Secondary end-points included the volume of the endometriotic nodule, pelvic tenderness and the visual appearance of endometriotic lesions at laparoscopy. RESULTS: Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). However, no effect of infliximab was observed for any of the outcome measures. After surgery, pain scores decreased in both groups to less than 20% of the initial value. CONCLUSIONS: Infliximab appears not to affect pain associated with deep endometriosis. Treatment is associated with an important placebo effect. After surgery, pain decreases to less than 20%. Trials registration number ClinicalTrials.gov: NCT00604864